Diagnostic value of circulating microRNAs in thyroid carcinoma: A systematic review and meta-analysis.
circulating microRNAs
diagnosis
meta-analysis
thyroid cancer
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
19
11
2019
revised:
08
04
2020
accepted:
27
04
2020
pubmed:
8
5
2020
medline:
19
8
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
Thyroid cancer (TC) is the most common endocrine system tumour. Several studies had revealed the potential of circulating microRNAs (miRNAs) as novel biomarkers for the diagnosis of TC. The purpose of this meta-analysis is to summarize published studies and evaluate the diagnostic accuracy of circulating miRNAs in TC detection. In this meta-analysis, we systematically searched three databases: PubMed, EMBASE and Cochrane Library. We used the bivariate mixed-effects regression model to calculate the pooled diagnostic parameters and conduct the summary receiver operator characteristic curve (SROC). All calculations were performed using stata software. Thirty-five studies from 9 articles, including 663 TC patients, 519 patients with benign thyroid nodules (BTNs), and 84 healthy controls were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the SROC curve (AUC) were 0.81 (95% CI 0.75-0.86), 0.81 (95% CI 0.75-0.86), 4.3 (95% CI 3.2-5.6), 0.24 (95% CI 0.18-0.31), 18 (95% CI 12-28) and 0.88 (95% CI 0.85-0.90), respectively in BTN controls, and 0.81 (95% CI 0.75-0.86), 0.85 (95% CI 0.75-0.91), 5.3 (95% CI 3.3-8.7), 0.23 (95% CI 0.18-0.29), 24 (95% CI 14-39), 0.89 (95% CI 0.86-0.91) in healthy controls. The subgroup analysis found that multiple miRNA assays had higher diagnostic accuracy than single miRNA assays with sensitivity of 0.88, specificity of 0.89 and AUC of 0.94. Circulating miRNAs have good values to diagnose TC and distinguish TC patients from BTN patients. MiRNAs can assist in the diagnosis of malignancy and avoid unnecessary surgery. In summary, circulating miRNAs should be added to our current clinical tools.
Sections du résumé
BACKGROUND AND OBJECTIVE
Thyroid cancer (TC) is the most common endocrine system tumour. Several studies had revealed the potential of circulating microRNAs (miRNAs) as novel biomarkers for the diagnosis of TC. The purpose of this meta-analysis is to summarize published studies and evaluate the diagnostic accuracy of circulating miRNAs in TC detection.
METHODS
In this meta-analysis, we systematically searched three databases: PubMed, EMBASE and Cochrane Library. We used the bivariate mixed-effects regression model to calculate the pooled diagnostic parameters and conduct the summary receiver operator characteristic curve (SROC). All calculations were performed using stata software.
RESULTS
Thirty-five studies from 9 articles, including 663 TC patients, 519 patients with benign thyroid nodules (BTNs), and 84 healthy controls were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the SROC curve (AUC) were 0.81 (95% CI 0.75-0.86), 0.81 (95% CI 0.75-0.86), 4.3 (95% CI 3.2-5.6), 0.24 (95% CI 0.18-0.31), 18 (95% CI 12-28) and 0.88 (95% CI 0.85-0.90), respectively in BTN controls, and 0.81 (95% CI 0.75-0.86), 0.85 (95% CI 0.75-0.91), 5.3 (95% CI 3.3-8.7), 0.23 (95% CI 0.18-0.29), 24 (95% CI 14-39), 0.89 (95% CI 0.86-0.91) in healthy controls. The subgroup analysis found that multiple miRNA assays had higher diagnostic accuracy than single miRNA assays with sensitivity of 0.88, specificity of 0.89 and AUC of 0.94.
CONCLUSION
Circulating miRNAs have good values to diagnose TC and distinguish TC patients from BTN patients. MiRNAs can assist in the diagnosis of malignancy and avoid unnecessary surgery. In summary, circulating miRNAs should be added to our current clinical tools.
Substances chimiques
Biomarkers
0
Biomarkers, Tumor
0
Circulating MicroRNA
0
MicroRNAs
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
489-498Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Samsonov R, Burdakov V, Shtam T, et al. Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer. Tumour Biol. 2016;37:12011-12021.
Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg. 2015;4:52-62.
Nixon AM, Provatopoulou X, Kalogera E, Zografos GN, Gounaris A. Circulating thyroid cancer biomarkers: Current limitations and future prospects. Clin Endocrinol. 2017;87:117-126.
Zheng J, Li J. Serum miRNA-203 as a potential biomarker for papillary thyroid carcinoma. Int J Clin Exp Med. 2016;9:14980-14986.
Xu J. The expression of plasma miR-663 and sHLA-G in papillary thyroid carcinoma and its diagnostic value. J Pract Oncol. 2019;34:332-336.
Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011;96:2016-2026.
Mahmood S, Bhatti A, Syed NA, John P. The microRNA regulatory network: a far-reaching approach to the regulate the Wnt signaling pathway in number of diseases. J Recept Signal Transduct Res. 2016;36:310-318.
George GP, Mittal RD. MicroRNAs: potential biomarkers in cancer. Indian J Clin Biochem. 2010;25:4-14.
Hu J, Li C, Liu C, Zhao S, Wang Y, Fu Z. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC. Cancer Biomark. 2017;18:87-94.
Zhou GJ, Xiao M, Zhao LN, Tang JG, Zhang L. MicroRNAs as novel biomarkers for the differentiation of malignant versus benign thyroid lesions: a meta-analysis. Genet Mol Res. 2015;14:7279-7289.
Salido-Guadarrama I, Romero-Cordoba S, Peralta-Zaragoza O, Hidalgo-Miranda A, Rodríguez-Dorantes M. MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. Onco Targets Ther. 2014;7:1327-1338.
Lee YS, Lim YS, Lee JC, et al. Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer. Oral Oncol. 2015;51(1):77-83.
Shabani N, Sheikholeslami S, Paryan M, et al. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients. J Cell Physiol. 2019;235(2):1366-1373.
Zhang Y, Xu D, Pan J, et al. Dynamic monitoring of circulating micrornas as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma. Oncology Letters. 2017;13:4252-4266.
Yu S, Liu Y, Wang J, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:2084-2092.
Zhang Y, Pan J, Xu D, et al. Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma. Oncol Rep. 2018;40:3611-3624.
Cantara S, Pilli T, Sebastiani G, et al. Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. J Clin Endocrinol Metab. 2014;99:4190-4198.
Castagna MG, MarzocchiC PilliT, ForleoR PaciniF, Cantara S. MicroRNA expression profile of thyroid nodules in fine-needle aspiration cytology: a confirmatory series. J Endocrinol Invest. 2019;42:97-100.
Cibas Edmund S, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27:1341-1346.
Hsiao SJ, Nikiforov Y. Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer. 2014;21:T301-T313.
Oczko-Wojciechowska M, Kotecka-Blicharz A, Krajewska J, et al. European perspective on the use of molecular tests in the diagnosis and therapy of thyroid neoplasms. Gland Surg. 2020;9(S2):S69-S76.
Wei WJ, Shen CT, Song HJ, Qiu ZL, Luo QY. MicroRNAs as a potential tool in the differential diagnosis of thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol. 2016;84:127-133.
Stokowy T, Wojtaś B, Fujarewicz K, Jarząb B, Eszlinger M, Paschke R. miRNAs with the potential to distinguish follicular thyroid carcinomas from benign follicular thyroid tumors: results of a meta-analysis. Horm Metab Res. 2014;46:171-180.